# Merck (MRK) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MRK
## Company Profile
- Ticker: MRK
- Exchange: NYSE
- Sector: Oncology, Immunotherapy, Vaccines
- Location: United States
- Tags: Vaccines, Immunotherapy, Oncology, Cardio-Metabolic
## Stock Data
- Close: 132.92 USD
- Market cap: 285635193594.75 USD
- Last updated: 2026-08-12
## Business Overview
Merck is a diversified pharmaceutical company with major exposure to oncology, vaccines, infectious disease, and animal health. The company’s market story still revolves around Keytruda, pipeline replacement, and the durability of its broader portfolio.
## Why The Stock Is Moving

As of Aug 12, 2026, MRK closed up 1.92% at $132.92. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, Merck has a global pharmaceutical footprint with strong international reach. It sits in large-cap biopharma and not in a narrow biotech niche.

## Business Model

Merck generates revenue from a mix of blockbuster products, vaccines, and pipeline assets. Investors watch oncology growth, patent lifecycle pressure, vaccine demand, and whether the next wave of products can offset concentration risk.

## Landscape Position

Merck is a mature large-cap pharma name with meaningful biotech-like catalyst sensitivity around oncology and vaccine updates. It is less volatile than clinical-stage companies, but major pipeline or label events can still move sentiment.

## Future Catalysts

- Merck’s next three months are likely to focus on Winrevair uptake, oncology execution, and any pipeline readout that helps replace the market’s dependence on Keytruda. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.

## Recent News
- No recent company news available.